PREDX
LIVE

Serial Number

79382300

Owner

Dermagnostix GmbH

Attorney

Nicholas Spencer Whitelaw

Filing Date

Sep 6, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PREDX Trademark

Serial Number: 79382300 • Registration: 7717724

PREDX is a trademark filed by Dermagnostix GmbH on September 6, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Dermagnostix GmbH

Georges-Köhler-Allee 302

Entity Type: 99

Trademark Details

Filing Date

September 6, 2023

Registration Date

March 11, 2025

Published for Opposition

January 21, 2025

Goods & Services

Apparatus for scientific research and use in laboratories, namely, biomarker test cartridges; diagnostic apparatus for measurement of biomarkers in the nature of genes, gene expression levels, and proteins, not for medical purposes; biochips for research or scientific purposes; microfluid biochips for research or scientific purposes; lab-on-a-chip systems comprised of biochips for research or scientific purposes; laboratory devices and instruments in the nature of centrifuges for analysis and evaluation of lab-on-a-chip systems; laboratory test trays

Medical instruments for measuring and testing biomarkers in tissue, cells, and liquids; tools for medical diagnostics, namely, biomarker test cartridges; apparatus for carrying-out diagnostic tests for medical purposes, namely, apparatus for measurement of biomarkers in the nature of genes, gene expression levels, and proteins

Medical diagnostic reagents and tests for testing of body fluids and tissue samples; chemical preparations for medical purposes and biochemical preparations for medical use and biotechnological preparations for medical use, namely, reagents, enzymes and buffer solutions, all for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; kits containing diagnostic preparations for medical purposes, in particular for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 10, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 23, 2025 FICS
FINAL DISPOSITION PROCESSED
Sep 23, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 11, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 19, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 31, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 31, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 11, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 15, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 24, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 24, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 24, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 24, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 24, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 16, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 16, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 16, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 16, 2024 TROA
REFUSAL PROCESSED BY IB
Jun 3, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 13, 2024 RFCS
REFUSAL PROCESSED BY MPU
May 13, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 4, 2024 RFCR
NON-FINAL ACTION WRITTEN
May 3, 2024 CNRT
ASSIGNED TO EXAMINER
May 2, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 2, 2023 REPR